24/7 Market News Snapshot 22 October, 2024 – ENDRA Life Sciences Inc. Common Stock (NASDAQ:NDRA)

October 22, 2024

DENVER, Colo., 22 October, 2024 (247marketnews.com) – (NASDAQ:NDRA) are discussed in this article.
ENDRA Life Sciences Inc. has garnered significant investor interest today, opening at $0.228 and experiencing a remarkable rise to $0.297, representing an increase of over 34.39% from the previous close of $0.221. This surge reflects heightened trading activity, with current volumes reaching 6.39 million shares. Such momentum indicates robust confidence among investors in ENDRA’s pioneering technologies and their potential for growth.

Simultaneously, the company is making strides in its clinical research with the initiation of a post-market clinical study focusing on its innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) liver system. This landmark study, which has begun with the first patient scan at a leading medical research facility, aims to collect real-world clinical data to evaluate the system’s effectiveness in measuring liver fat against the established MRI-PDFF test. The findings are anticipated to contribute significantly to validating TAEUS as an essential tool for managing metabolic diseases and could transform existing healthcare protocols.

Alexander Tokman, Acting CEO and Chairman of ENDRA, highlighted the collaboration with a prominent European academic institution, emphasizing its potential to enrich the company’s clinical data landscape. This partnership is crucial for supporting ENDRA’s upcoming FDA De Novo submission slated for mid-2025 and is expected to position TAEUS as a reliable biomarker for liver fat assessment.

Moreover, ENDRA’s TAEUS technology provides MRI-comparable tissue characterization at a fraction of the cost, thus enhancing accessibility at the point of care. Given the global prevalence of chronic liver diseases affecting over two billion individuals, ENDRA is poised to lead advancements in effective diagnostic solutions. As the company progresses with its clinical initiatives, it remains steadfast in its commitment to improving patient outcomes and transforming liver health assessment worldwide.

Related news for (NDRA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.